Sector Watch: Healthcare - Apr 27 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $105.61 +0.31 0.29% | XBI: $88.42 +0.58 0.66% | Updated Apr 27, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| NWBO Northwest Biotherapeutics $69.0M |
0.21+0.04 2.7 M 2.0x |
21% | ||
| CYAD Celyad SA $296.1M |
34.70+4.71 52.0 K 18.5x |
16% | ||
| BKD Brookdale Senior Living $1.4B |
7.42+0.89 6.3 M 1.8x |
14% | ||
| CHEK Check-Cap $281.0M |
9.02+1.06 2.2 M 4.7x |
13% | ||
| XENE52WH Xenon Pharmaceuticals $78.3M |
5.80+0.65 344.3 K 3.6x |
13% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| TLGT Teligent $163.6M |
3.11-0.45 3.1 M 3.4x |
-13% | ||
| IVTY52WL Invuity $81.8M |
3.20-0.30 240.6 K |
-9% | ||
| CGEN Compugen $191.8M |
3.55-0.30 403.4 K |
-8% | ||
| TRIL Trillium Therapeutics $86.1M |
6.05-0.50 94.3 K |
-8% | ||
| EYPT Eyepoint Pharmaceuticals $99.4M |
2.29-0.18 2.0 M 2.2x |
-7% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Teligent, Inc. Announces Agreements to Exchange Approximately $65 million of its 3.75% Senior Convertible Notes Due 2019 for 4.75% Senior Convertible Notes Due 2023 [globenewswire.com]Ventas Reports 2018 First Quarter Results | Business Wire [businesswire.com]
Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class [prnewswire.com]
Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody [prnewswire.com]
Brookdale Enters into Mutually-Beneficial Agreements with Ventas [prnewswire.com]
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient [globenewswire.com]
Teligent, Inc. to Hold Conference Call for First Quarter 2018 Results [globenewswire.com]
Xenon Pharmaceuticals to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference [globenewswire.com]
Epilepsy: Competitive Landscape, Market and Pipeline Analysis 2018 - Analysis of 115+ Therapeutic Drugs - ResearchAndMarkets.com | Business Wire [businesswire.com]
Invuity Announces 2018 First Quarter Financial Results and Conference Call Date [globenewswire.com]
Check-Cap Regains Compliance With Nasdaq Minimum Bid Price Requirement [prnewswire.com]
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information Nasdaq:PSDV [globenewswire.com]
EyePoint Pharmaceuticals? YUTIQ? for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting [globenewswire.com]
Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting [globenewswire.com]
Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05% [globenewswire.com]
Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024 - ResearchAndMarkets.com | Business Wire [businesswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
